Comparing Full and Shortened Gadoxetate-enhanced MRI for Detecting Liver Metastases in Colorectal Cancer Patients Evaluating Diagnostic Accuracy, Patient Outcomes, and Economic Impact

What this Trial Is About

Researchers are evaluating the accuracy and economic impact of two MRI protocols using the contrast agent gadoxetate Primovist to detect liver metastases in patients diagnosed with colorectal cancer. This study compares a full-length Primovist MRI protocol with a shortened version to see if the shorter exam can provide similar detection accuracy while reducing scan time and costs. The trial is prospective, randomized, and aims to improve imaging efficiency and patient management for colorectal liver metastases. Participants will be randomly assigned to receive either the routine full Primovist MRI or a shortened Primovist MRI with fewer pulse sequences. The baseline MRI scan will occur between 2 and 14 days after enrollment. Follow-up imaging with contrast-enhanced CT of the abdomen and pelvis will be performed one year later to assess cancer progression. The study plans to enroll 200 patients, with 100 in each group. During the trial, participants will undergo MRI scans with intravenous contrast to highlight liver lesions. Researchers will evaluate diagnostic accuracy, inter-reader agreement, survival outcomes at one year, and economic costs related to both MRI protocols and subsequent patient management. The primary outcome focuses on diagnostic accuracy over two years, while secondary outcomes include cost and survival data assessed over three years. Safety and tolerability of the MRI procedure will also be monitored throughout the study.

Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer